Welcome to our dedicated page for STAAR SURGICAL CO SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on STAAR SURGICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into STAAR SURGICAL CO's regulatory disclosures and financial reporting.
STAAR Surgical director Christopher Min Fang Wang received a grant of stock options, acquiring rights to 11,145 shares of common stock. The options have an exercise price of $29.12 per share and were granted as compensation, not through open-market buying or selling.
These options vest in full on the earlier of June 18, 2027 or the company’s 2026 annual meeting of shareholders, and expire on June 18, 2036. After this grant, Wang holds 11,145 options directly under this award.
STAAR Surgical director Richard T. LeBuhn received a new stock option grant as part of his director compensation. He was granted options covering 11,145 shares of common stock at an exercise price of $29.12 per share, with no cash paid for the grant.
These options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. LeBuhn also holds previously granted options covering 7,524 shares at an exercise price of $18.46 per share that are currently exercisable and expire in 2036.
STAAR Surgical director Neal C. Bradsher reported a new stock option grant as director compensation. He received options for 11,145 shares of common stock at an exercise price of $29.12 per share, expiring on June 18, 2036.
The new options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, contingent on his continued service. Bradsher also holds previously granted options covering 7,524 underlying shares at an exercise price of $18.46 per share, which are currently exercisable.
STAAR Surgical Company reported results from its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders approved Amendment No. 2 to the Amended and Restated Omnibus Equity Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 3,900,000 shares.
Seven directors were elected to serve until the 2027 annual meeting or until successors are elected and qualified. Shareholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending January 1, 2027 and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. As of April 20, 2026, there were 49,788,295 outstanding common shares, and a quorum of 43,680,435 shares was represented at the meeting.
STAAR Surgical director Arthur C. Butcher exercised 5,341 restricted stock units into Common Stock on June 18, 2026, bringing his direct Common Stock holdings to 9,549 shares.
He also received 3,709 new restricted stock units and 4,458 stock options at a $29.12 exercise price, which vest in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Shareholders.
Zhou Lilian Yansheng reported acquisition or exercise transactions in this Form 4 filing.
STAAR Surgical director Lilian Yansheng Zhou received new equity awards as part of the company’s annual non-employee director compensation for the 2026-2027 term. On June 18, 2026, Zhou was granted options to purchase 5,572 shares of common stock at $29.12 per share, expiring June 17, 2036.
Zhou also received 3,091 restricted stock units tied to common stock. According to the grant terms, both the options and the restricted stock units vest in full on the earlier of June 18, 2027 or STAAR Surgical’s 2027 Annual Meeting of Shareholders.
STAAR Surgical director Lou Silverman reported compensation-related equity activity. He exercised 10,683 previously granted restricted stock units into an equal number of common shares and now directly holds 11,158 shares. On the same date, he received a new grant of 6,182 restricted stock units for the 2026–2027 non‑employee director term, which will vest in full on the earlier of June 18, 2027 or the company’s 2027 annual shareholder meeting. All transactions reflect equity awards and exercises rather than open‑market buying or selling.
STAAR Surgical director Jiang Wei reported equity compensation transactions involving company stock. On June 18, 2026, Jiang Wei exercised 10,683 previously granted restricted stock units into 10,683 shares of common stock, increasing direct common share holdings to 77,127 shares after the transactions.
On the same date, Jiang Wei received a new grant of 6,182 restricted stock units under the annual non-employee director equity compensation program for the 2026-2027 term. These new units are scheduled to vest in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Shareholders.
STAAR Surgical director Lilian Yansheng Zhou acquired 3,530 shares of common stock on June 12, 2026 as a grant or award-type transaction. The weighted average price reported was $28.2904 per share, based on multiple trades between $28.215 and $28.35. Following this acquisition, Zhou directly holds 8,101 shares of STAAR Surgical common stock.
STAAR Surgical Company updated the compensation of Deborah Andrews, its Interim Co-Chief Executive Officer and Chief Financial Officer. Effective June 8, 2026, her annual base salary increases from $512,000 to $575,000. Her target annual cash bonus also rises from 55% to 60% of base salary, reflecting a review of market data and her contributions to the company’s strategic and operational objectives.